21st.BIO A/S - CVR: 41554908

2022, DKK

23.05.2023

Bruttoresultat

-21.931'

Primær drift

-55.447'

Årets resultat

-36.612'

Aktiver

329''

Kortfristede aktiver

75.079'

Egenkapital

263''

Afkastningsgrad

-17 %

Soliditetsgrad

80 %

Likviditetsgrad

+500%

Resultat

23.05.2023

Årsrapport	2022 23.05.2023	2020 27.05.2022
Nettoomsætning
Bruttoresultat	-21.930.501	-19.455.071
Resultat af primær drift	-55.446.884	-22.263.534
Indtægter af kapitalandele (tilknyttede og associerede)	0	0
Finansielle indtægter	304.185	85.558
Finansieringsomkostninger	0	0
Andre finansielle omkostninger	-817.651	-80.835
Resultat før skat	-54.208.668	0
Resultat	-36.612.241	-21.795.858
Forslag til udbytte	0	0

Aktiver

23.05.2023

Årsrapport	2022 23.05.2023	2020 27.05.2022
Kortfristede varebeholdninger	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	25.792.104	7.613.040
Likvider	49.286.568	24.302.544
Kortfristede aktiver	75.078.672	31.915.584
Immaterielle aktiver og goodwill	245.453.520	0
Finansielle anlægsaktiver	3.432.577	521.711
Materielle aktiver	5.423.207	1.527.019
Langfristede aktiver	254.309.304	2.048.730
Aktiver	329.387.976	33.964.314

Aktiver

23.05.2023

Passiver

23.05.2023

Årsrapport	2022 23.05.2023	2020 27.05.2022
Forslag til udbytte	0	0
Egenkapital	262.615.831	23.854.142
Hensatte forpligtelser	54.185.278	0
Langfristet gæld til banker	0	0
Anden langfristet gæld	0	0
Leverandører af varer og tjenesteydelser	11.777.539	9.054.049
Kortfristede forpligtelser	12.586.867	10.110.172
Gældsforpligtelser	12.586.867	10.110.172
Forpligtelser	12.586.867	10.110.172
Passiver	329.387.976	33.964.314

Passiver

23.05.2023

Nøgletal

23.05.2023

Årsrapport	2022 23.05.2023	2020 27.05.2022
Afkastningsgrad	-16,8 %	-65,5 %
Dækningsgrad	Na.	Na.
Resultatgrad	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.
Egenkapitals-forretning	-13,9 %	-91,4 %
Payout-ratio	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.
Soliditestgrad	79,7 %	70,2 %
Likviditetsgrad	596,5 %	315,7 %

Resultat

23.05.2023

Gæld

23.05.2023

Årsrapport

23.05.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 23.05.2023)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C. The accounting policies applied to these financial statements are consistent with those applied last year.

Oplysning om pantsætninger og sikkerhedsstillelser:8 Assets charged and collateralThe company has not issued assets charged and collateral .

Beretning

23.05.2023

Dato for ledelsens godkendelse af årsrapporten:2023-05-09

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of 21st. BIO A/S for the financial year 01. 01. 2022 - 31. 12. 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activities21st. BIO is a bio-industrial scale-up company founded on a mission to support bio-industrial companies globally in upscaling from molecule innovation to large-scale production. This allows customers to compete effectively and meet market demands for biobased solutions. Thereby our customers advance the green transition globally. The focus areas of 21st. BIO include proteins and peptides that can be utilized for the food, materials and agricultural industries. 21st. BIO builds on select technologies from Novozymes A/S and helps customers develop their expression platform and process for large-scale production of their particular molecule by testing the molecule using various expression platforms, such as fungi, yeast or bacteria. When the right expression platform has been identified, 21st. BIO draws on its comprehensive strain bank and selects and optimizes the best-performing strains and develops a downstream process for it. This leads to an optimized production platform that enables clients to produce their product at commercially attractive costs and quantities, in turn leading to an increase in the likelihood of a successful launch and a decrease in time to market.